Management of Locoregional Melanoma

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Adjuvant immunotherapy has improved melanoma treatment outcomes.
• Neoadjuvant immunotherapy offers enhanced benefits for advanced melanoma.
• Current prognostication is limited by the absence of reliable biomarkers for treatment response or disease progression.

Purpose of the Study:

• To highlight the need for reliable biomarkers in melanoma management.
• To emphasize the potential of biomarkers in guiding clinical decisions for high-risk patients.
• To underscore the importance of investigating biomarkers for immune response and gene expression.

Main Methods:

• Review of current immunotherapy strategies in melanoma.
• Analysis of the limitations in prognostication and treatment individualization.
• Exploration of active research areas for biomarker development.

Main Results:

• Immunotherapy, both adjuvant and neoadjuvant, has shown significant clinical benefits in melanoma.
• The lack of predictive biomarkers hinders accurate prognostication and personalized treatment.
• Investigating biomarkers related to innate antitumor immunity and gene expression is ongoing.

Conclusions:

• Reliable biomarkers are essential for improving prognostication and individualizing treatment in melanoma.
• Biomarker development could enhance clinical decision-making for patients with high-risk melanoma.
• Further research into immune activation and gene expression biomarkers is critical for advancing melanoma care.